Kaleido Biosciences

General Information


We are a clinical-stage healthcare company with a differentiated, chemistry-driven approach focused on leveraging the potential of the microbiome organ to treat disease and improve human health. We have built a human-centric proprietary product platform for discovery and development that we believe will enable the rapid advancement of a broad portfolio of novel product candidates into non-IND human clinical studies under regulations supporting research with food. Our product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome by driving the function and distribution of the organ’s existing microbes.

Employees: 118
Founded: 2015
Contact Information
Address 65 Hayden Avenue, Lexington, MA 02421, US
Phone Number (617) 674-9000
Web Address https://www.kaleido.com
View Prospectus: Kaleido Biosciences
Financial Information
Market Cap $444.5mil
Revenues $0 mil (last 12 months)
Net Income $-61.7 mil (last 12 months)
IPO Profile
Symbol KLDO
Exchange NASDAQ
Shares (millions): 5.0
Price range $15.00 - $15.00
Est. $ Volume $75.0 mil
Manager / Joint Managers Goldman Sachs/ J.P. Morgan/ Morgan Stanley
CO-Managers Canaccord Genuity
Expected To Trade: 2/28/2019
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change